Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Footsie gives up gains

Mon, 11th Jan 2010 16:41

The leading share index gave up early gains to finish only slightly higher as euphoria over strong trade figures from China in December gave way to renewed fears over recovery prospects. China's December imports jumped by 55.9% from the same month the previous year, while exports were 17.7% higher. Continued demand for commodities was behind much of the rise, with crude oil imports climbing 25% and copper imports up by more than a quarter.Oil company Cairn Energy was a strong performer after positive noises from Citigroup. The broker says that fast-tracking the multi-well exploration drilling programme in Greenland has made the group its preferred play on frontier exploration in 2010. Dana is its value play while Tullow could be the most exciting story over the first quarter.Elsewhere in the sector, BP and Shell advanced as oil hit a 15-month high.But miners, which had been among the top risers after the Chinese data came out, gave up these gains in afternoon trading. Silver miner Fresnillo slipped back after it dropped out of the race for Canadian mining company Canplats Resources. Eurasian Natural Resources, Vedanta Resources, Anglo American and Xstrata also closed lower.Bank Barclays has received its third upbeat broker note in less than a week. This time it is Citigroup that reckons the bank is cheap, adding that the market is applying too low a rating to Barclays' earnings. Citigroup's target price is 413p, implying 30% upside.Property groups Land Securities and British Land climbed after the former was added to Goldman Sachs' 'conviction buy' list. Segro, which updated on trading today, rose after Goldman upgraded its rating on the stock to 'neutral'. Inès Reinman, Segro's head of Continental Europe, has resigned from the industrial property group barely a year she was promoted to the board. "Current trading and market conditions are in line with our expectations at the time of our Interim Management Statement issued on 5 November 2009," chief executive Ian Coull added.SABMiller fell after it pulled out of the race to buy the Femsa stable of beer brands leaving the way clear for rival brewer Heineken.Cash strapped plumbers merchant Wolseley is to raise just under £24m from the sale of its Irish businesses. WIBHM, a company backed by private investor, is paying €26.5m for Wolseley Ireland Holdings Limited. The exceptional loss on disposal, excluding currency impacts, is expected to be around €55m (£50m).Online gaming group PartyGaming has tied up an an exclusive, five-year agreement with state-controlled Danske Spil to provide an online gaming platform for poker and casino games in Denmark. Outdoor clothing retailer Blacks Leisure said it is mulling a possible equity fundraising in the first quarter to raise between £15m and £20m depending on investor demand. It hopes to roll out new stores, having closed 87 loss-making outlets in the fourth quarter of 2009. It said trading in the ongoing stores was very healthy with like-for-like sales increasing by 12.0% in the half year ended 7 JanuaryThe US Navy has awarded defence and aerospace group Cobham a contract worth up to $11.5m for the UK group. Cobham has won the Band 5/6 TWT (Travelling-wave Tube) Replacement Module Assembly (TRMA) development contract.Stem cell therapy group ReNeuron said it is on track to start human trials of its flagship treatment ReN001 for disabled stroke patients in the first quarter of this year.EMED Mining's quest to reopen the Rio Tinto mine in Spain moved a step closer following recent court rulings deemed favourable to the company. The cases all related to objections by previous stakeholders in the mine.FTSE 100 - RisersLand Securities Group (LAND) 683.00p +2.86%TUI Travel (TT.) 271.00p +2.69%British Land Co (BLND) 473.40p +2.60%BG Group (BG.) 1,223.00p +2.43%Marks & Spencer Group (MKS) 375.00p +2.35%Cairn Energy (CNE) 370.30p +2.32%Kingfisher (KGF) 230.80p +2.30%BP (BP.) 635.50p +2.22%SEGRO (SGRO) 350.70p +1.95%Morrison (Wm) Supermarkets (MRW) 290.20p +1.90%FTSE 100 - FallersEurasian Natural Resources (ENRC) 1,010.00p -2.32%Standard Chartered (STAN) 1,590.00p -2.09%Legal & General Group (LGEN) 82.55p -2.08%SABMiller (SAB) 1,801.00p -2.01%Prudential (PRU) 626.50p -1.88%Man Group (EMG) 314.00p -1.81%Vedanta Resources (VED) 2,834.00p -1.80%Anglo American (AAL) 2,845.00p -1.79%Xstrata (XTA) 1,224.50p -1.76%Fresnillo (FRES) 852.00p -1.62%FTSE 250 - RisersRenishaw (RSW) 602.00p +5.61%St James's Place (STJ) 270.00p +5.47%Electra Private Equity (ELTA) 1,280.00p +5.09%Interserve (IRV) 229.90p +5.07%Lamprell (LAM) 211.00p +4.87%BlueBay Asset Management (BBAY) 347.40p +4.48%Halfords Group (HFD) 436.00p +4.31%Dechra Pharmaceuticals (DPH) 493.00p +4.23%Telecity Group (TCY) 424.00p +3.95%Domino Printing (DNO) 353.60p +3.66%FTSE 250 - FallersImagination Technologies (IMG) 262.80p -5.81%Weir Group (WEIR) 798.00p -4.09%Carphone Warehouse Group (CPW) 192.20p -2.88%Close Brothers Group (CBG) 712.00p -2.40%Unite Group (UTG) 289.10p -2.36%Barratt Developments (BDEV) 138.70p -2.26%Charter International (CHTR) 770.00p -2.10%SIG (SHI) 122.80p -1.92%DS Smith (SMDS) 125.70p -1.80%Investec (INVP) 454.80p -1.69%
More News
11 Mar 2013 08:31

ReNeuron Group wins grants for stem cell therapy development

ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy. The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council. The first award of £0.4m will be used for

Read more
29 Jan 2013 10:29

ReNeuron Group edges further in stem cell therapy research for stroke patients

ReNeuron Group received the green light to complete the final stages of first phase safety testing of its ReN001 stem cell therapy for disabled stroke patients in Scotland, the company announced Tuesday. The ReN001 stem cell therapy was being administered in ascending doses to a total of 12 stroke

Read more
5 Nov 2012 08:33

Angel Biotech signs new contract with ReNeuron

Angel Biotechnology, a manufacturer of stem cells for medical research, has announced a new contract with ReNeuron for completion in the current financial year. The contract is to supply clinical material for ReNeuron's research trials using stem cells to treat stroke patients. ReNeuron's ReN001

Read more
17 Oct 2012 07:27

ReNeuron progresses stroke clinical trial

ReNeuron has reported further progress in the clinical trial of its ReN001 stem cell therapy for disabled stroke patients, known as the PISCES study. The third and penultimate batch of three patients have all been successfully treated with ReN001 and discharged from hospital with no acute safety is

Read more
11 Sep 2012 14:25

Small caps round-up: ReNeuron, Havelock, Goodwin

Clinical-stage stem cell group ReNeuron has achieved further significant milestones with its ReN001 and ReN009 programmes in stroke and critical limb ischaemia, with the filing of two further clinical trial applications to progress the clinical development of these novel therapies. Michael Hunt, Chi

Read more
14 Aug 2012 12:35

Small caps round-up: ReNeuron, Eckoh, Healthcare Locums

Clinical-stage stem cell group ReNeuron surged on Tuesday after saying that the Data Safety Monitoring Board gave a favourable recommendation to proceed to the with a higher dose of its ReN001 stem cell therapy in a clinical trial. 'This represents a further important milestone for the study as we m

Read more
28 Jun 2012 14:22

ReNeuron's full-year results disappoint

ReNeuron Group, a UK-based stem cell company, suffered a decline in its share price on Thursday after posting an increase in pre-tax losses for the year ended March 31st. Loss before tax widened from £6.64m to £6.8m year-on-year (y/y), while revenues rose from £0.029m to £0.04m, representing royal

Read more
16 May 2012 15:18

Small caps round-up: Sepura, ReNeuron, Angel Bio ...

Sepura, the developer and supplier of TETRA digital radios, has acquired 3T Communications, a supplier of TETRA infrastructure, for an initial cash consideration of 8m euros. The final price could increase by up to 5m euros, depending on 3T's trading performance. Austrian firm 3T designs and impleme

Read more
27 Apr 2012 14:20

Small caps round-up: James Cropper, ValiRx, ReNeuron

James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea

Read more
3 Apr 2012 12:39

Small caps round-up: DQ Entertainment, Tristel, ReNeuron

DQ Entertainment, a producer of animation, visual effects, game art and live action entertainment content for the global media and entertainment industry, has won three new contracts for co-production. The first is with French broadcaster TF1 for the new 3D animated TV series of Robin Hood, the seco

Read more
11 Jan 2012 10:55

ReNeuron down despite positive data release

In its second announcement of the year, ReNeuron, the Surrey based stem cell developer, has announced new data on the stability of the company's CTX stem cell line. Researchers from University College London are due to tell a conference in San Diego that the results show "CTX cells retained their m

Read more
3 Jan 2012 08:19

ReNeuron announces positive data

Stem cells therapy developer ReNeuron has gained positive data from a recent pre-clinical study which used its ReN001 stem cell therapy for disabled stroke patients. The newly-published data show significantly improved outcomes in the key behavioural tests in the cell-treated group. A gradual im

Read more
13 Sep 2011 15:09

ReNeuron successfully treats first patient

Stem cells therapy developer ReNeuron has successfully treated a stroke patient who underwent the safe, first-time administration of a higher dose of its new drug, ReN001. The firm ran the increased level of the stem cell therapy drug after the independent Data Safety Monitoring Board recommended t

Read more
13 Dec 2010 18:06

ReNeuron cash call will last two years

Stem cell therapies developer ReNeuron is raising £10m from a share issue at 5.5p a share. The cash will finance the pre-clinical and clinical development costs of the main drug programmes, as well as general running costs, for the next two years. The cash will also be used to complete manufacturi

Read more
12 Jul 2010 08:31

Small caps round-up: Ariana Resources, Michelmersh, ReNeuron...

Shares in Ariana Resources rallied after the Turkey-focused gold miner announces the completion of its joint venture agreement with Proccea to develop the Red Rabbit Project in western Turkey. The group said results from the recent resource drilling programme are expected shortly. Managing directo

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.